Last reviewed · How we verify
Semaglutide Pill — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Semaglutide Pill (Semaglutide Pill) — Medanta, The Medicity, India.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Semaglutide Pill TARGET | Semaglutide Pill | Medanta, The Medicity, India | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Semaglutide Pill CI watch — RSS
- Semaglutide Pill CI watch — Atom
- Semaglutide Pill CI watch — JSON
- Semaglutide Pill alone — RSS
Cite this brief
Drug Landscape (2026). Semaglutide Pill — Competitive Intelligence Brief. https://druglandscape.com/ci/semaglutide-pill. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab